Release Date: 7/1/10
Expiration Date: 6/30/11
Jointly-sponsored by ArcMesa and the University of Cincinnati
 
This activity has been approved for 7 AMA PRA Category 1 CreditsTM.
Activity Description
Prostate cancer is one of the most common cancers in men, affecting 1 out of every 6 men in the United States. Each year, it is diagnosed in 234,460 men and approximately 27,000 die as a result. Patients with this disease may be treated by urologists, radiation oncologists, medical oncologists, or a combination of these specialists, depending on their tumor stage, rate of progression, and life expectancy. Although 91% of all prostate cancer cases are detected at an early (localized) stage, management has not yet been perfected and metastasis is a common occurrence. Fortunately, continued progress has been made in the treatment of prostate cancer over the past 5 years, and improvements in both strategies and available therapeutic agents have increased survival rates for patients with prostate cancer.
On March 27, 2010, ArcMesa Educators hosted its Third Annual Interdisciplinary Prostate Cancer Congress (IPCC) at the Grand Hyatt Hotel in New York City. This full-day continuing medical education (CME) activity entitled, Translating Advances into Clinical Practice was jointly sponsored by the University of Cincinnati and ArcMesa Educators and is a continuing effort dedicated to addressing the differences that currently exist between urologists’, medical oncologists’ and radiation oncologists’ approaches to treating prostate cancer.
This CME program was co-chaired by Dr. Leonard Gomella from Thomas Jefferson University and Dr. Daniel Petrylak from Columbia University College of Physicians and Surgeons. In addition, Dr. Roy Berger, Dr. E. David Crawford, Dr. Robert Dreicer and Dr. Howard Sandler rounded out the faculty panel for this symposium. These world-renowned thought leaders have been brought together to foster consensus about the best management of prostate cancer from the vantage point of interdisciplinary care teams. Among several topics of vital interest to these groups of clinicians, the IPCC addressed hormonal therapies, imaging and staging, surgical advances, radiation therapies and emerging multi-modal therapies. The IPCC concluded with a set of interactive case-based presentations designed to highlight multidisciplinary approaches for the management of prostate cancer with the overall goal of improving patient outcomes.
Webcast Accreditation & Credit Designation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and ArcMesa Educators.
The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians. The University of Cincinnati designates this educational activity for a maximum of seven (7) AMA PRA Category 1Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Learner Assurance Statement
The University of Cincinnati is committed to resolving all conflict of interest issues that could arise as a result of prospective faculty members’ significant relationships with drug or device manufacturer. The University of Cincinnati is committed to retaining only those speakers with financial interests that can be reconciled with the goals and educational integrity of the CME activity.
How to Receive Credit
By reviewing the course content and successfully completing the evaluation, physicians are entitled to receive 7 AMA PRA category 1 credits™. Statement of credit will be available to print.
Target Audience
Urologists, medical oncologists and radiation oncologists who treat patients with prostate cancer
Educational Objectives
- Review the current treatment options for patients with localized, androgen-dependent, and hormone refractory and/or castrate metastatic prostate cancer and apply them to clinical practice
- Identify the disparities among current practice guidelines for prostate cancer management and select the guidelines they will use in their clinical practice
- Evaluate the results of recent clinical trials investigating the efficacy and safety of emerging agents and determine when these emerging treatments should be utilized in their current patient population
- Formulate an interdisciplinary plan for their patients with prostate cancer
Grant Support
This CME activity is supported by educational grants from:
Centocor Ortho Biotech Services LLC
ImClone Systems (a wholly-owned subsidiary of Eli Lilly and Company)
sanofi-aventis U.S.
Staff Disclosure Declarations
The employees of ArcMesa Educators have no financial relationships to disclose.
Disclosures
Leonard G. Gomella, MD
Advisory Board – Watson, Ferring, GlaxoSmithKline, AstraZeneca
Consultant – sanofi-aventis
Investigator – GlaxoSmithKline, Vivus
Daniel P. Petrylak, MD
Advisory Board – Celgene, sanofi-aventis, AstraZeneca, Ferring, ImClone
Consultant – Celgene, sanofi-aventis, AstraZeneca, Ferring, ImClone, Egenix
Grant Recipient – Celgene, Merck & Co. Inc., Boehringer Ingelheim, Dendreon Corporation, ImClone Systems, AstraZeneca, GlaxoSmithKline,
Progenix Pharmaceuticals, Amgen, sanofi-aventis
Speaker’s Bureau – Ferring
Other – Prostate Conditions Education Council
E. Roy Berger, MD
Advisory Board – Dendreon Corporation
Consultant – Dendreon Corporation
Speaker’s Bureau – sanofi-aventis
E. David Crawford, MD
Advisory Board – Ferring
Consultant – Elgen
Grant Recipient – University of Colorado Cancer Center, NIH
Speaker’s Bureau – Watson, sanofi-aventis, GlaxoSmithKline, Ferring
Other – Endo, Oncura, Endocare
Employee – Ferring (family member)
Robert Dreicer, MD
Advisory Board – Celgene, AstraZeneca, Ortho, Endo, EMD Serono
Consultant – Transgene
Howard M. Sandler, MD, MS
Advisory Board – Genentech, Centocor
Consultant – Calypso, Iris, sanofi-aventis
Officer or Board Member – ITA Partners
Shareholder – Tomotherapy, Biogen
|
Leonard G. Gomella, MD
The Bernard W. Godwin Professor of Prostate Cancer
Chairman
Department of Urology
Associate Director of Clinical Affairs
Jefferson Kimmel Cancer Center Thomas Jefferson University
Thomas Jefferson University
Philadelphia, PA
Daniel P. Petrylak, MD
Director, Prostate Cancer Program
Professor of Medicine at NYPH/CUMC
Herbert Irving Comprehensive Cancer Center
Columbia University/New York Presbyterian Hospital
Columbia University College of Physicians and Surgeons
New York, NY
E. Roy Berger, MD
Clinical Assistant Professor of Medicine
Stony Brook University School of Medicine
Stony Brook, NY
E. David Crawford, MD
Professor of Surgery and Radiation Oncology
Head of the Section on Urologic Oncology
University of Colorado Health Sciences Center (UCHS)
Denver, CO
Robert Dreicer, MD
Chairman Department of Solid Tumor Oncology
Taussig Cancer Institute
Cleveland Clinic
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, OH
Howard M. Sandler, MD, MS
Ronald H. Bloom Chair in Cancer Therapeutics
Professor and Chair, Department of Radiation Oncology
Cedars-Sinai Medical Center
Los Angeles, CA
|
Disclosure Policy
It is the policy of ArcMesa Educators that our staff and faculty disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentations. Individuals who refuse to disclose will be disqualified from all aspects of this CME activity. ArcMesa Educators has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
Disclaimer
©2010 ArcMesa Educators. All rights reserved. None of the contents may be reproduced in any form without prior written permission from ArcMesa Educators.
The views and opinions expressed in this activity are those of the faculty. They do not reflect the views of any other manufacturer of pharmaceuticals, ArcMesa Educators.
The recommendations made in this program are based upon a combination of randomized clinical trials, current guidelines, and the clinical practice experience of the participating faculty. Any medications, diagnostic procedures or treatments discussed by the faculty should not be utilized without evaluation of their patient’s conditions. Participants are urged to consult the full prescribing information on any drug mentioned in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Hardware/Software Requirements
System Requirement: Windows 98, ME, 2000, XP, Vista; Mac OS X.
Windows: Intel Pentium II 450 mhz or faster processor (or equivalent), 128MB of RAM.
Mac: PowerPC G3 500mhz or faster processor, 128MB of RAM.
Internet/Network: Broadband connectivity.
ArcMesa Educators requires Microsoft Internet Explorer 5.5, Firefox 1.x, Netscape 7.x, Opera 7.11, Safari 1.x or later. Certain educational activities may require additional software to view multimedia, presentation or printable versions of their content. That software may be: Adobe Flash Player 8, Apple Quicktime, Adobe Acrobat, Microsoft Powerpoint, Windows Media Player, and Real Networks Real One Player.
Technical Support
Metaball Creative
948 Alden Bridge Drive Cary, NC 27519
Phone/Fax: 888-675-6289 | Email: getintouch@metaballcreative.com
Customer Services
ArcMesa Educators, LLC
Address: 666 Plainsboro Rd, Suite 440, Plainsboro, NJ 08536
Phone: 800-597-6372 | Fax: 609-228-5894 | Email: info@arcmesa.org
|
